DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...

Abiomed, part of Johnson & Johnson MedTech, recently presented positive results from the first completed pivotal trial on Impella ECP, a novel transvalvular axial flow pump with compressible pump ...

Results were presented at Transcatheter Cardiovascular Therapeutics, or TCT, 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson said Monday that a pivotal trial for the ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...

Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...

Abiomed, Inc. ABMD announced receipt of the FDA’s breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Bestowing of the designation implies that the FDA will ...

Abiomed might be on the verge of being acquired by Johnson & Johnson, but that doesn’t mean the milestones have to stop. FDA has approved the version of the Danvers, MA-based company’s heart pump that ...

Danvers, Mass.-based medical device company Abiomed received the FDA’s breakthrough device designation for its Impella ECP heart pump. The designation means the FDA will prioritize the device’s ...

Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart ...